Alok Ranjan
Stanford University, University of Texas Southwestern Medical Center, National Chemical Laboratory CSIR, V.B.S.Puravanchal University
0000-0001-9906-4044
About
I am Alok Ranjan, Ph.D., a Research Scientist in the Department of Chemistry at Stanford University, California, USA. My research focuses on synthetic organic chemistry, medicinal chemistry, chemical biology, drug discovery, and drug delivery. I work at the interface of chemistry, biology, and medicine, with an emphasis on the design and synthesis of biologically active small molecules, natural product-inspired therapeutics, PKC modulators, and advanced drug transport systems.
I completed my Ph.D. in Organic Chemistry at the Indian Institute of Technology Kanpur, India, in 2016. During my doctoral research, I worked on the enantioselective total synthesis of marine toxins, oxazinins, antimalarial flinderole natural products, and one-pot multicomponent syntheses of biologically relevant heterocycles, including imidazole-2-(thi)ones, thiazolidine-2-ylideneamines, and 2-amino-1,3-selenazoles. This training strengthened my ability to independently design, plan, and execute challenging synthetic chemistry projects and led to multiple peer-reviewed publications.
My current and long-term scientific interests include function-oriented synthesis, natural product-inspired drug discovery, medicinal chemistry optimization, heterocyclic chemistry, PKC modulator development, drug delivery systems, and translational chemical biology. My goal is to continue developing innovative chemical approaches that address important unmet medical needs, including resistant cancers, HIV/AIDS, multiple sclerosis, and neurodegenerative diseases such as Alzheimer’s disease.
Employment
-
Stanford University Postdoctoral Fellow2018 - Present
-
University of Texas Southwestern Medical Center Postdoctoral Fellow2016 - 2018
Education
-
National Chemical Laboratory CSIR Research Fellow2009 - 2011
-
V.B.S.Puravanchal University M.Sc.2004 - 2006
Projects & Funding
Projects & funding information is unavailable.
Publications (19)
- Leveraging HIV-Specific CAR T Cells and Rapamycin Treatment in “Kick-and-Kill” HIV Cure Approaches Save
- PKC inhibitors reveal PKC isoforms involved in HIV latency reversal and immunomodulation. Save
- Organ- and Cell-Selective Delivery of mRNA In Vivo Using Guanidinylated Serinol Charge-Altering Releasable Transporters Save
- Defining the Effects of PKC Modulator HIV Latency-Reversing Agents on Natural Killer Cells Save
- Novel orexin receptor agonists based on arene- or pyridine-fused 1,3-dihydro-2H-imidazole-2-imines Save
- Charge-altering releasable transporters enhance mRNA delivery in vitro and exhibit in vivo tropism Save
- Evaluation of the efficacy of the hypocretin/orexin receptor agonists TAK‐925 and ARN‐776 in narcoleptic orexin/tTA; TetO‐DTA mice Save
- Secreted factors induced by PKC modulators do not indirectly cause HIV latency reversal Save
- Trimethylene Methane Dianion Equivalent for the Asymmetric Consecutive Allylation of Aldehydes: Applications to Prins-Driven Macrocyclizations for the Synthesis of Bryostatin 1 and Analogues Save
- Evaluation of the Efficacy of the Hypocretin/orexin Receptor Agonists TAK-925 and ARN-776 in NarcolepticOrexin/tTA; TetO-DTAMice Save